

- 1. Childbearing age female with any of the following (1) abdominal/pelvic pain, (2) adnexal mass, (3) vaginal bleeding, (4) syncope, (5) dizziness
- 2. Serum quantitative βHCG result should not delay bedside ultrasound. It is not required to confirm definitive IUP by bedside ultrasound.
- 3. Patient with a history assisted reproductive fertility (including in vitro fertilization or ovulation induction agents)
- 4. Definitive IUP: Gestational sac with yolk sac/fetal pole
- 5. Definitive EP: Gestational sac containing clearly defined yolk sac or fetal pole outside of endometrial cavity (including cornua)
- 6. RhoGAM (50 mcg IM if < 12 wks, 300 mcg IM if > 12 wks) for vaginal bleeding/Rh (-)
- 7. "Discrimanatory Zone" is the Quantitative HCG above which an IUP should be seen in single gestations
- 8. Methotrexate dosing: 50 mg/m2 IM
- 9. High risk features: h/o tubal ligation or tubal surgery, PID, previous EP, technically inadequate US, adnexal masses, moderate to large amount of free fluid in the cul de sac, bHCG>3500.
- 10. Contraindication to Methotrexate: Hemodynamically unstable, Intra-uterine/heterotopic desired pregnancy, Breast Feeding, Immunodeficiency or immunosuppresion, inability to follow up, Alcoholism, Pre-existing liver disease or dysfunctions, Hypersensitivity to Methotrexate, Active Pulmonary Disease, Peptic Ulcer Disease, Renal Dysfunction, severe anemia, leukopenia, thrombocytopenia, ectopic >3.5cm (relative)
- Ob/gyn consultation may be a telephone consult if appropriate. If discrepancy, an attending to attending discussion should occur to decide on the need for in person vs. telephone consultation. All consultations (telephone/video/in person) must result in a consult note in the medical record.